B2ARM

B2ARM is an armored chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of multiple myeloma. It consists of primary human T cells genetically engineered to express a CAR targeting the B-cell maturation antigen (BCMA) alongside a dominant-negative TGF-β receptor type II (TGF-β DNRII). This armoring strategy is specifically designed to overcome the immunosuppressive tumor microenvironment of the bone marrow, where transforming growth factor-beta (TGF-β) typically inhibits T-cell function and persistence. By co-expressing the DNRII, B2ARM cells are resistant to TGF-β-mediated suppression of activation, effector differentiation, and cytotoxicity. Preclinical studies have demonstrated that B2ARM CAR T cells exhibit superior persistence, proliferation, and anti-tumor efficacy compared to conventional, non-armored BCMA CAR T cells.

Other names

armored BCMA CAR T cellsB2-TGFβDNRII CAR T cellsBCMA-targeting CAR with TGF-β dominant-negative receptor II